Drug Proprietary Name Selection: Draft Guidance Calls For Simulation Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance on developing proprietary drug names recommends series of steps for sponsors to evaluate a proposed name; safety review includes testing name with healthcare professionals.